ABBOTT LABORATORIES (ABT) Risk Factors
Health CareLatest 10-K filed Feb 20, 2026Source: SEC EDGAR
WealthWire extracted and classified 20 risk factors from ABBOTT LABORATORIES’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.
Legal & regulatory
5 factorsTechnology
3 factorsFinancial
3 factorsOperations & people
3 factorsMarket & business
3 factorsHealthcare & life sciences
2 factorsOther
1 factorsRecent key developments
Concrete developments — dated events, named agreements and instruments, legal proceedings — that ABBOTT LABORATORIES surfaced in its latest filing.
- In February 2022, Abbott initiated a voluntary recall of certain powder infant formula products manufactured at its Sturgis, Michigan facility and temporarily stopped manufacturing at the facility.February 2022
- In May 2022, Abbott entered into a consent decree with the FDA.May 2022
- Abbott plans to fund the Exact Sciences acquisition with approximately $20 billion of borrowings, incurring additional indebtedness.
- As of December 31, 2025, Abbott's consolidated indebtedness was approximately $12.9 billion.December 31, 2025
- The ongoing Russia-Ukraine conflict has resulted in sanctions, economic and currency volatility, higher inflation, heightened cybersecurity risks, and operational and supply chain disruptions.
Go deeper on ABT
This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for ABT and every other S&P 500 company.